Page 58 - 82_03

Arantxa Rodríguez Casado, Adolfo Toledano-Díaz, Adolfo Toledano
reticulum stress. Proc Natl Acad Sci USA
2011;108:2939-44.
62. Hoozemans JJ, Van Haastert ES, Nijholt DA,
Rozemuller AJ, Eikelenboom P, Scheper W. The
unfolded protein response is activated in pretangle
neurons in Alzheimer's disease hippocampus. Am J
Pathol 2009;174:1241-51.
63. Lourenco MV, Clarke JR, Frozza RL, Bomfim TR,
Forny-Germano L, Batista AF, Sathler LB, Brito-
Moreira J, Amaral OB, Silva CA, Freitas-Correa L,
Espírito-Santo S, Campello-Costa P, Houzel JC, Klein
WL, Holscher C, Carvalheira JB, Silva AM, Velloso
LA, Munoz DP, Ferreira ST, DeFelice FG. TNF-a
mediates PKR-dependent memory impairment and
brain IRS-1 inhibition induced by Alzheimer's ß-
amyloid oligomers in mice and monkeys. Cell Metab
2013;18:831-43.
64. Banks WA. Blood-brain barrier transport of cytokines:
a mechanism for neuropathology. Curr Pharm Des.
2005;11:973-84.
65. Sonnen JA, Larson EB, Brickell K, Crane PK, Woltjer
R, Montine TJ, Craft S. Different patterns of cerebral 73. Kosicek M, Hecimovic S. Phospholipids and
injury in dementia with or without diabetes. Arch
Neurol 2009;66:315-22. 8. Smith U. Abdominal
obesity: a marker of ectopic fat accumulation. J Clin
Invest 2015;125:1790-2.
66. Kitazawa M, Cheng D, Tsukamoto MR, Koike MA,
Wes PD, Vasilevko V, Cribbs DH, LaFerla FM.
Blocking IL-1 signaling rescues cognition, attenuates
tau pathology, and restores neuronal ß-catenin
pathway function in an Alzheimer's disease model. J
Immunol 2011;187:6539-49.
67. Sly LM, Krzesicki RF, Brashler JR, Buhl AE,
McKinley DD, Carter DB, Chin JE. Endogenous brain
cytokine mRNA and inflammatory responses to
lipopolysaccharide are elevated in the Tg2576
transgenic mouse model of Alzheimer's disease. Brain
Res Bull 2001;56:581-8.
68. DeFelice FG, Vieira MN, Bomfim TR, Decker H,
316 @Real Academia Nacional de Farmacia. Spain
Velasco PT, Lambert MP, Viola KL, Zhao WQ,
Ferreira ST, Klein WL. Protection of synapses against
Alzheimer's-linked toxins: insulin signaling prevents
the pathogenic binding of Abeta oligomers. Proc Natl
Acad Sci USA 2009;106:1971-6.
69. Craft S. Alzheimer disease: Insulin resistance and AD-
extending the translational path. Nat Rev Neurol
2012;8:360-2.
70. Moloney AM, Griffin RJ, Timmons S, O'Connor R,
Ravid R, O'Neill C. Defects in IGF-1 receptor, insulin
receptor and IRS-1/2 in Alzheimer's disease indicate
possible resistance to IGF-1 and insulin signalling.
Neurobiol Aging 2010;31:224-43.
71. Zhu X, Lee HG, Raina AK, Perry G, Smith MA. The
role of mitogen-activated protein kinase pathways in
Alzheimer's disease. Neurosignals 2002;11:270-81.
72. Miloso M, Scuteri A, Foudah D, Tredici G. MAPKs as
mediators of cell fate determination: an approach to
neurodegenerative diseases. Curr Med Chem
2008;15:538-48.
Alzheimer's disease: alterations, mechanisms and
potential biomarkers. Int J Mol Sci 2013;14:1310-22.
74. Kaidanovich O, Eldar-Finkelman H. The role of
glycogen synthase kinase-3 in insulin resistance and
type 2 diabetes. Expert Opin Ther Targets 2002;6:555-
61.
75. Kim B, Feldman EL. Insulin resistance in the nervous
system. Trends Endocrinol Metab 2012;23:133-41.
76. Bales KR. Brain lipid metabolism, apolipoprotein E
and the pathophysiology of Alzheimer's disease.
Neuropharmacology 2010;59:295-302.
77. Talbot K, Wang HY. The nature, significance, and
glucagon-like peptide-1 analog treatment of brain
insulin resistance in Alzheimer's disease. Alzheimers
Dement 2014;10:S12-25.
78. Huang PL. A comprehensive definition for metabolic
syndrome. Dis Model Mech 2009;2:231-7.